Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality9/10

CorMedix Delivers Strong Q2, Expands DefenCath Footprint; Short Interest Signals Upside

Aug 13, 2026, 12:29 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Robust Q2 results, expanded DefenCath footprint, and a strong cash position enhance fundamentals and visibility. Elevated short interest could amplify moves around key catalysts (REZZAYO sNDA in Q3) and contract news, a common pattern in small-cap healthcare names.

AI summary

What happened, with direct paths to the underlying reporting

CorMedix posted robust Q2 results led by DefenCath-driven revenue and a strong cash position, with 2026 guidance reaffirmed. A multi-year DefenCath supply agreement expands the footprint to all five of the largest U.S. dialysis providers, and an sNDA for REZZAYO is anticipated in Q3. A high short interest adds a potential near-term upside catalyst.

CRMD Q2 revenue $101.9M; DefenCath $66.1M, Melinta $35.8M.
Net income $26.0M; adjusted EBITDA $58.7M.
Cash and short-term investments $256.7M as of June.
New multi-year DefenCath supply agreement expands to all top five U.S. dialysis providers.
Short interest 16.28M shares, >17 days to cover as of July 31.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.